Article Sidebar

Published: 2026-07-26
Abstract Views: 0
DOI: https://doi.org/10.52163/yhc.v67i7.5950
Issue
Tập 67 No 7
Section
Articles
How to Cite
Hoàng, N. V., Minh, Đặng Đức, Phương, Đặng T. T., Phương, Đặng T. T., & Tú, T. T. (2026). CLINICAL AND PARACLINICAL CHARACTERISTICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS WITH METABOLIC SYNDROME TREATED AT THAI NGUYEN NATIONAL HOSPITAL. Vietnam Journal of Community Medicine, 67(7). https://doi.org/10.52163/yhc.v67i7.5950

CLINICAL AND PARACLINICAL CHARACTERISTICS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS WITH METABOLIC SYNDROME TREATED AT THAI NGUYEN NATIONAL HOSPITAL

Nguyen Viet Hoang1, Dang Duc Minh1,2, Dang Thi Thanh Phuong1, Dang Thi Thanh Phuong1, Tran Tuan Tu1,2
1 Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen University
2 Thai Nguyen National Hospital

Main Article Content

Abstract

Objective: To describe the clinical and paraclinical characteristics of chronic obstructive pulmonary disease (COPD) patient with metabolic syndrome, and to analyze the association between each component of metabolic syndrome and COPD severity according to the GOLD classification.


Subjects and Methods: A cross sectional descriptive study was conducted on 109 COPD patients with metabolic syndrome who were treated as inpatients and outpatients at the Department of Respiratory Medicine, Thai Nguyen National Hospital, from August 2024 to August 2025.


Results: The mean age of the study population was 69.23 ± 9.38 years, with males accounting for 89.9%. Common clinical symptoms included dyspnea and productive cough; frequent physical findings were reduced breath sounds and barrel chest. Most patients were classified as GOLD stage II–III. Chest X ray findings commonly showed emphysema and bronchial lesions. The most prevalent components of metabolic syndrome were hypertension (77.1%), hypertriglyceridemia (72.5%), and elevated fasting blood glucose (71.6%). The majority of patients had three components of metabolic syndrome (83.5%). Hypertension was associated with COPD severity according to the GOLD classification, with a statistically significant difference (p = 0.028). 


Conclusion: COPD patient with metabolic syndrome in this study were predominantly elderly males, with most classified as GOLD stage II–III. Hypertension, hypertriglyceridemia, and elevated fasting blood glucose were the most common components of metabolic syndrome; among these, hypertension showed a statistically significant association with COPD severity.

Article Details

Keywords

Chronic obstructive pulmonary disease, metabolic syndrome, GOLD.

References

1. Agusti, A., et al., Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med, 2023. 207(7): p. 819-837. doi: 10.1183/13993003.00239-2023.
2. Boers, E., et al., Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. JAMA Netw Open, 2023. 6(12): p. e2346598. doi: 10.1001/jamanetworkopen.2023.46598.
3. Lam, H.T., et al., Prevalence of COPD by disease severity in men and women in northern Vietnam. COPD, 2014. 11(5): p. 575-81. doi: 10.3109/15412555.2014.898039.
4. Alberti, K.G., et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009. 120(16): p. 1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644.
5. Mariniello, D.F., et al., Comorbidities in COPD: Current and Future Treatment Challenges. J Clin Med, 2024. 13(3):743. doi: 10.3390/jcm13030743.
6. Watz, H., et al., The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest, 2009. 136(4): p. 1039-1046. doi: 10.1378/chest.09-0393.
7. Chan, S.M.H., et al., Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther, 2019. 198: p. 160-188. doi: 10.1016/j.pharmthera.2019.02.013.
8. Alrabbaie, H., et al., The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: A systematic review and meta-analysis. Chron Respir Dis, 2025. 22: p. 14799731251346194. doi: 10.1177/14799731251346194.
9. Venkatesan, P., GOLD COPD report: 2024 update. Lancet Respir Med, 2024. 12(1): p. 15-16. doi: 10.1016/S2213-2600(23)00461-7.
10. Vũ Thanh Bình., et al., Tỷ lệ hội chứng chuyển hóa ở bệnh nhân mắc bệnh phổi tắc nghẽn mạn tính. Tạp chí Y Dược Thái Bình, 2022(2): p. 69-73.
11. Wang, Z., et al., Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study. BMC Pulm Med, 2023. 23(1): p. 394. doi: 10.1186/s12890-023-02702-2.
12. Diez-Manglano, J., et al., COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med, 2014. 9(4): p. 419-25. doi: 10.1007/s11739-013-0945-7.